What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?

  • Bioanalysis. 2018 May 1;10(10):723-735. doi: 10.4155/bio-2018-0027.
Jérôme Vialaret  1 ,  Sophie Broutin  2 ,  Célia Pugnier  1 ,  Sophie Santelé  1 ,  Aurore Jaffuel  3 ,  Alan Barnes  4 ,  Laurent Tiers  1 ,  Laurent Pelletier  4 ,  Sylvain Lehmann  1 ,  Angelo Paci  2 ,  Christophe Hirtz  1
Affiliations
  • 1. University of Montpellier, LBPC- IRMB, CHU Montpellier, 80 rue Augustin Fliche, Montpellier, France.
  • 2. Service de Pharmacologie, Département de Biologie et Pathologie Médicales, Gustave Roussy et Université Paris Saclay, Villejuif, France.
  • 3. Shimadzu Corporation, Marne-la-Vallée, France.
  • 4. Shimadzu Corporation, Manchester, UK.
PMID: 29771137 DOI: 10.4155/bio-2018-0027
Abstract

Aim: Monoclonal antibody-based treatment of Cancer has been established as one of the most successful therapeutic strategies.

Materials & methods: In this work, we developed a workflow based on an automated protein-A capture and LC-MS/MS analysis to quantify bevacizumab on patient serum during treatment. This analytical approach was fully validated and compared with a commercially available Monoclonal antibody-based treatment preparation (nanosurface and molecular-orientation limited kit).

Results: The analytical comparison of the two preparative workflows based on protein-A capture gave similar results with a better lower limit of quantification for the nanosurface and molecular-orientation limited kit (0.26986 vs 1.9565 μg/ml).

Conclusion: LC-MS/MS has clear advantages compared with ELISA when considering method development time, multiplexing capacities and absolute quantification with internal standardization.

Keywords
MS; automation; bevacizumab; nSMOL; protein-A purification; therapeutic drug monitoring.
Products